EpiCast Report: Endometriosis - Epidemiology Forecast to 2022

Publisher Name :
Date: 25-Sep-2013
No. of pages: 38

Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in a series of chronic inflammatory reactions leading to scarring of tissues and adhesions of fibrous tissues in the pelvic region. Globally, the disease affects up to 10% of women. The condition is often associated with severe dysmenorrhea, chronic pelvic pain, chronic fatigue, deep dyspareunia, ovulation pain, abnormal bleeding and infertility.

The report provides an overview of the risk factors and global and historical trends for endometriosis in the 6MM. In addition, the report also includes a 10-year epidemiological forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15-49 years) and stages. GlobalData epidemiologists forecast that the diagnosed prevalent cases of endometriosis in the 6MM will grow from 5.66 million cases in 2012 to 5.86 million cases in 2022, at a growth rate of 3.4% over the forecast period.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of endometriosis in the 6MM, from 5.66 million prevalent cases in 2012 to 5.86 million prevalent case in 2022, at a growth rate of 3.4% over the forecast period. The US constituted the largest proportion (almost 90%) of the prevalent cases of endometriosis, with 5.24 million prevalent cases in 2022. Endometriosis is not a life-threatening condition and is largely influenced by hereditary factors. However, the condition will cause substantial economic, physical and psycho-social burden to the individual, as well as to the healthcare system, during the forecast period.

Scope


  • The Endometriosis EpiCast Report provides an overview of the risk factors and global trends of endometriosis in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiology forecast of the diagnosed prevalent cases of endometriosis segmented by age (in 5-year increments for women ages 15-49 years) and stages.

  • The endometriosis epidemiology report is written and developed by Mastersand PhD-level epidemiologists.

  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.


Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global endometriosis market.

  • Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for endometriosis therapeutics in each of the markets covered.

EpiCast Report: Endometriosis - Epidemiology Forecast to 2022

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5

2 Introduction 6
2.1 Catalyst 6

3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 9
3.2.1 Family history is a strong predictor for the risk of endometriosis 10
3.2.2 Late age at menarche protects women from developing endometriosis 11
3.2.3 Higher parity decreases the risk for endometriosis 12
3.3 Global Trends 13
3.3.1 US 14
3.3.2 5EU 15
3.4 Forecast Methodology 16
3.4.1 Sources Used 17
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods 20
3.5 Epidemiological Forecast of Endometriosis (2012-2022) 22
3.5.1 Diagnosed Prevalent Cases of Endometriosis 22
3.5.2 Age-Specific Prevalent Cases of Endometriosis 23
3.5.3 Age-Standardized Prevalence of Endometriosis 25
3.5.4 Diagnosed Prevalent Cases of Endometriosis by Stage 26
3.6 Discussion 27
3.6.1 Epidemiological Forecast Insight 27
3.6.2 Limitations of the Analysis 28
3.6.3 Strengths of the Analysis 30

4 Appendix 31
4.1 Bibliography 31
4.2 About the Authors 34
4.2.1 Epidemiologists 34
4.2.2 Reviewers 34
4.2.3 Global Director of Epidemiology and Health Policy 36
4.2.4 Global Head of Healthcare 36
4.3 About GlobalData 37
4.4 About EpiCast 37
4.5 Disclaimer 37

List of Tables

Table 1: Stages of Endometriosis (as per American Society of Reproductive Medicine) 8
Table 2: Risk Factors for Endometriosis 9
Table 3: Epidemiological Sources for Diagnosed Prevalence and Stages of Endometriosis 16
Table 4: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022 22
Table 5: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, Row (%), 2012 24
Table 6: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stages, Ages 15-49 Years, N, Row (%), 2012 26

List of Figures

Figure 1: 6MM, Diagnosed Prevalent Cases of Endometriosis, Ages 15-49 Years, N, 2012-2022 23
Figure 2: 6MM, Prevalent Cases of Diagnosed Endometriosis, by Age, N, 2012 24
Figure 3: 6MM, Age-Standardized Prevalence (%) of Diagnosed Endometriosis, Ages 15-49 Years, 2012 25
Figure 4: 6MM, Prevalent Cases of Diagnosed Endometriosis by Stage, Ages 15-49 Years, 2012 27

  • Global Contraceptives Sales Market Report 2016
    Published: 28-Nov-2016        Price: US 4000 Onwards        Pages: 114
    Notes: Sales, means the sales volume of Contraceptives Revenue, means the sales value of Contraceptives This report studies sales (consumption) of Contraceptives in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - The Female Health Company - Teva Pharmaceutical Industries Ltd. - Reckitt Ben......
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016
    Published: 16-Nov-2016        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2016, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary......
  • Vasomotor Symptoms of Menopause-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Vasomotor Symptoms of Menopause-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Vasomotor Symptoms of Menopause. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licens......
  • Vulvovaginal Candidiasis-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Vulvovaginal Candidiasis-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Vulvovaginal Candidiasis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collabora......
  • Dysmenorrhea-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Dysmenorrhea-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Dysmenorrhea Report is to understand the market and pipeline status of the drugs around the Dysmenorrhea to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing......
  • Eclampsia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Eclampsia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Eclampsia Report is to understand the market and pipeline status of the drugs around the Eclampsia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline......
  • Dysmenorrhea-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Dysmenorrhea-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Dysmenorrhea. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fun......
  • Uterine fibroids - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Uterine fibroids - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Uterine fibroids forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report ......
  • Endometriosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Endometriosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Endometriosis Report is to understand the market and pipeline status of the drugs around the Endometriosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on design......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs